logo
Plus   Neg
Share
Email

Pfizer: FDA Approves ABRILADA As Biosimilar To Humira - Quick Facts

Pfizer Inc. (PFE) announced the FDA has approved ABRILADA as a biosimilar to Humira for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.

ABRILADA is a tumor necrosis factor or TNF blocker and biosimilar to Humira. It targets and blocks TNF, which is believed to help reduce inflammation.

Pfizer said the company is working to make ABRILADA available to U.S. patients as soon as feasible based on the terms of its agreement with AbbVie. The company's current plans are to launch in 2023.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration has granted accelerated approval to Tazverik for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Epithelioid sarcoma is a rare sub-type of soft... STIHL recalls about 16,400 STIHL RE 90 pressure washers due to injury hazard. According to the company, the recalled pressure washer nozzle can disconnect from the spray wand when under pressure during use, posing an injury hazard. STIHL said it received seven reports of the nozzle detaching from... CVS Health Corp. launched 13 new HealthHUB locations in CVS Pharmacy stores across Philadelphia and South New Jersey. The healthcare company said it developed the HealthHUB store format to help people manage chronic conditions more conveniently and affordably. The store also features health and wellness products, clinical services and expertise.
Follow RTT
>